The fragility of randomized placebo-controlled trials for irritable bowel syndrome.
MaryJane O WilliamsMary SedarousBrittany DennisVanessa DlaminiObioma NwaiwuLinda A NguyenPhilip N OkaforPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)
A median of six participants is needed to nullify results in the included IBS trials suggesting how easily statistical significance based on a threshold p-value may be overturned.